Adenocarcinoma of Lung Clinical Trial
Official title:
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
NCT number | NCT05665504 |
Other study ID # | MCC-21767 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 11, 2023 |
Est. completion date | February 2028 |
This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | February 2028 |
Est. primary completion date | February 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer [clinical stage IA-IB (cT1a-T2aN0), <4cm diameter]. - If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center. - If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center. - >18 years old, male or female. - ECOG performance status 0-1. - Agree to participate in the follow-up protocol. - Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma). - Ability to understand and the willingness to sign a written, informed consent document. Exclusion Criteria: - Participants who are actively receiving any cancer treatment. - Participants with uncontrolled intercurrent illness. - Prior lung cancer within 5 years. - Current active other major cancer except non-melanoma skin cancer. - Patients with pure ground glass opacities (nodules) or hilar masses. - Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma). - Metastatic nodule (suspected) in the lung from an extrapulmonary cancer. - Patient unable to provide informed consent. - Prisoner or incarcerated individual. - For surgical patients, a R1 or R2 resection. |
Country | Name | City | State |
---|---|---|---|
United States | Moffitt Cancer Center | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
H. Lee Moffitt Cancer Center and Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease Free Survival | Disease-free survival (DFS) is defined as the time from surgical resection and adjuvant chemotherapy to recurrence of tumor or death | Up to 5 years | |
Primary | Overall Survival | Overall survival (OS) is defined as the time (days) from the date of surgical resection and adjuvant chemotherapy to the date of death, due to any reason. | Up to 5 Years | |
Secondary | Tumor Malignancy | Fisher exact test will used to test association of both LCDT1™ and NodifyXL2® blood tests with malignancy. | At 6 Months | |
Secondary | Cancer Recurrence | Fisher exact test will used to test association of LCDT-1™ blood test with cancer recurrence. | At 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04122833 -
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
|
||
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04027946 -
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Not yet recruiting |
NCT05079022 -
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
|
Phase 1/Phase 2 | |
Completed |
NCT02616211 -
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
|
||
Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
Recruiting |
NCT05550961 -
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
|
||
Active, not recruiting |
NCT05292859 -
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
|
||
Not yet recruiting |
NCT05565677 -
Prognostic Value of Lung Cancer MicroAnatomy in 3D
|
||
Completed |
NCT05252676 -
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)
|
||
Recruiting |
NCT03838588 -
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
|
||
Recruiting |
NCT04105270 -
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
|
Phase 2 | |
Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
Completed |
NCT00073398 -
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04770688 -
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
|
Phase 1/Phase 2 | |
Completed |
NCT04165759 -
HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)
|
||
Completed |
NCT04086680 -
The Detection of EGFR Mutations in Liquid Based Cytology Samples
|
||
Completed |
NCT01362790 -
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03298763 -
Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer
|
Phase 1/Phase 2 |